Clinicopathologic Characteristics, Progression, and Prognostic Analysis of IPNB
NCT06887023 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 118
Last updated 2025-03-20
Summary
The main aim of this observational study is to understand the clinicopathological and prognostic information of IPNB, a rare tumor. The participants have already received treatment during their previous routine medical management and took part in follow - up. We will look into their survival information after previous medical visits and treatment.
Conditions
- Bile Duct Neoplasms Malignant
Sponsors & Collaborators
-
The First Hospital of Jilin University
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-01
- Primary Completion
- 2025-01-15
- Completion
- 2025-02-01
Countries
- China
Study Locations
More Related Trials
-
Case Series Study of Biliary Tract Cancer Patients in Japan
NCT01294085 ·Status: COMPLETED
-
Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome
NCT01494324 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related Gene
NCT01786980 ·Status: COMPLETED
-
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
NCT05010668 ·Status: COMPLETED ·Phase: PHASE2
-
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
NCT05292443 ·Status: WITHDRAWN
-
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
NCT06851104 ·Status: TERMINATED ·Phase: PHASE2
-
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
NCT06644430 ·Status: RECRUITING
-
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
NCT07070700 ·Status: RECRUITING ·Phase: PHASE2
-
Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
NCT05520788 ·Status: RECRUITING
-
Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology
NCT02727673 ·Status: COMPLETED
-
Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT
NCT06408753 ·Status: COMPLETED
-
Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
NCT05184400 ·Status: RECRUITING
-
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
NCT02828124 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Biomarker Discovery in Patients With Advanced Biliary Tract Cancer
NCT04871321 ·Status: COMPLETED
-
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
NCT06849180 ·Status: RECRUITING
-
The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer
NCT02809898 ·Status: UNKNOWN
-
Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)
NCT05835245 ·Status: RECRUITING ·Phase: PHASE2
-
The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
NCT06746194 ·Status: RECRUITING
-
Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma
NCT02178280 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
NCT05281926 ·Status: UNKNOWN ·Phase: PHASE1
-
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
NCT04220944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies
NCT05487443 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Photodynamic Therapy for Cholangiocarcinoma
NCT04860154 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer
NCT06282120 ·Status: RECRUITING
-
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
NCT06530784 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2